Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 395

1.

Therapy of breast cancer brain metastases: challenges, emerging treatments and perspectives.

Kotecki N, Lefranc F, Devriendt D, Awada A.

Ther Adv Med Oncol. 2018 Jun 22;10:1758835918780312. doi: 10.1177/1758835918780312. eCollection 2018. Review.

2.

[Retroperitoneal mixed malignant mullerian tumor : exceptional localisation and prognosis].

El Hachem G, Jungels C, Larsimont D, Awada A.

Rev Med Brux. 2018;39(3):146-149. doi: 10.30637/2018.17-072. French.

PMID:
29964388
3.

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.

Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, Aftimos PG, Bekradda M, Rezai K, Zeng Z, Hussain A, Perez S, Siu LL, Massard C.

J Clin Oncol. 2018 May 7:JCO2018782292. doi: 10.1200/JCO.2018.78.2292. [Epub ahead of print]

PMID:
29733771
4.

Drug-Eluting Resorbable Magnesium Scaffold Implantation in ST-Segment Elevation Myocardial Infarction: A Pilot Study.

de Hemptinne Q, Picard F, Briki R, Awada A, Silance PG, Dolatabadi D, Debbas N, Unger P.

J Invasive Cardiol. 2018 Jun;30(6):202-206. Epub 2018 Apr 15.

5.

Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol.

Rugo HS, Cortes J, Awada A, O'Shaughnessy J, Twelves C, Im SA, Hannah A, Lu L, Sy S, Caygill K, Zajchowski DA, Davis DW, Tagliaferri M, Hoch U, Perez EA.

Clin Cancer Res. 2018 Apr 4. doi: 10.1158/1078-0432.CCR-17-3059. [Epub ahead of print]

PMID:
29618616
6.

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.

Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J.

J Clin Oncol. 2018 Mar 20;36(9):884-890. doi: 10.1200/JCO.2016.71.3495. Epub 2018 Jan 26.

PMID:
29373071
7.

Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer.

Başaran GA, Twelves C, Diéras V, Cortés J, Awada A.

Cancer Treat Rev. 2018 Feb;63:144-155. doi: 10.1016/j.ctrv.2017.12.002. Epub 2017 Dec 6. Review.

PMID:
29329006
8.

PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies.

Perdrix A, Najem A, Saussez S, Awada A, Journe F, Ghanem G, Krayem M.

Cancers (Basel). 2017 Dec 16;9(12). pii: E172. doi: 10.3390/cancers9120172. Review.

9.

Mechanical properties of resin-ceramic CAD-CAM materials after accelerated aging.

Blackburn C, Rask H, Awada A.

J Prosthet Dent. 2018 Jun;119(6):954-958. doi: 10.1016/j.prosdent.2017.08.016. Epub 2017 Nov 29.

PMID:
29195816
10.

Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer.

Solinas C, Garaud S, De Silva P, Boisson A, Van den Eynden G, de Wind A, Risso P, Rodrigues Vitória J, Richard F, Migliori E, Noël G, Duvillier H, Craciun L, Veys I, Awada A, Detours V, Larsimont D, Piccart-Gebhart M, Willard-Gallo K.

Front Immunol. 2017 Oct 30;8:1412. doi: 10.3389/fimmu.2017.01412. eCollection 2017.

11.

Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types.

Lonez C, Verma B, Hendlisz A, Aftimos P, Awada A, Van Den Neste E, Catala G, Machiels JH, Piette F, Brayer JB, Sallman DA, Kerre T, Odunsi K, Davila ML, Gilham DE, Lehmann FF.

BMJ Open. 2017 Nov 12;7(11):e017075. doi: 10.1136/bmjopen-2017-017075.

12.

Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients.

Awada G, de Azambuja E, Awada A.

Expert Opin Drug Metab Toxicol. 2017 Dec;13(12):1205-1215. doi: 10.1080/17425255.2017.1398733. Epub 2017 Nov 6. Review.

PMID:
29088977
13.

Echocardiographic demonstration of a thrombus straddling the patent foramen ovale and pulmonary embolism.

Awada A, de Cannière D, Silance PG, Unger P.

Eur Heart J Cardiovasc Imaging. 2018 Mar 1;19(3):358. doi: 10.1093/ehjci/jex256. No abstract available.

PMID:
29088333
14.

New Drug Combination Strategies in Melanoma: Current Status and Future Directions.

Najem A, Krayem M, Perdrix A, Kerger J, Awada A, Journe F, Ghanem G.

Anticancer Res. 2017 Nov;37(11):5941-5953. Review.

PMID:
29061773
15.

Hepatoid Adenocarcinoma of the Stomach: A Challenging Diagnostic and Therapeutic Disease through a Case Report and Review of the Literature.

Fakhruddin N, Bahmad HF, Aridi T, Yammine Y, Mahfouz R, Boulos F, Awada A, Farhat F.

Front Med (Lausanne). 2017 Sep 28;4:164. doi: 10.3389/fmed.2017.00164. eCollection 2017.

16.

TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.

Specenier PM, Remenar E, Buter J, Schrijvers DL, Bergamini C, Licitra LF, Awada A, Clement PM, Fortpied C, Menis J, Vermorken JB.

Ann Oncol. 2017 Sep 1;28(9):2219-2224. doi: 10.1093/annonc/mdx300.

17.

Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

Cortés J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, O'Shaughnessy J.

Breast Cancer Res Treat. 2017 Nov;166(1):327-328. doi: 10.1007/s10549-017-4482-3. No abstract available.

PMID:
28884461
18.

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.

Aftimos P, Rolfo C, Rottey S, Offner F, Bron D, Maerevoet M, Soria JC, Moshir M, Dreier T, Van Rompaey L, Michot JM, Silence K, Hultberg A, Gandini D, de Haard H, Ribrag V, Peeters M, Thibault A, Leupin N, Awada A.

Clin Cancer Res. 2017 Nov 1;23(21):6411-6420. doi: 10.1158/1078-0432.CCR-17-0613. Epub 2017 Aug 1.

PMID:
28765328
19.

P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.

Najem A, Krayem M, Salès F, Hussein N, Badran B, Robert C, Awada A, Journe F, Ghanem GE.

Eur J Cancer. 2017 Sep;83:154-165. doi: 10.1016/j.ejca.2017.06.033. Epub 2017 Jul 21.

PMID:
28738256
20.

How to emerge from the conservatism in clinical research methodology?

Kotecki N, Penel N, Awada A.

Curr Opin Oncol. 2017 Sep;29(5):400-404. doi: 10.1097/CCO.0000000000000399. Review.

PMID:
28704211
21.

The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives.

Kourie HR, Awada G, Awada A.

Immunotherapy. 2017 Jun;9(8):647-657. doi: 10.2217/imt-2017-0029. Review.

PMID:
28653570
22.

Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study.

Psyrri A, Fortpied C, Koutsodontis G, Avgeris M, Kroupis C, Goutas N, Menis J, Herman L, Giurgea L, Remenár É, Degardin M, Pateras IS, Langendijk JA, van Herpen CML, Awada A, Germà-Lluch JR, Kienzer HR, Licitra L, Vermorken JB.

Ann Oncol. 2017 Sep 1;28(9):2213-2218. doi: 10.1093/annonc/mdx320.

PMID:
28651338
23.

Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

Cortés J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, O'Shaughnessy J.

Breast Cancer Res Treat. 2017 Sep;165(2):329-341. doi: 10.1007/s10549-017-4304-7. Epub 2017 Jun 13. Erratum in: Breast Cancer Res Treat. 2017 Nov;166(1):327-328.

24.

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M.

Lancet Oncol. 2017 Jul;18(7):904-916. doi: 10.1016/S1470-2045(17)30376-5. Epub 2017 May 30.

25.

Controversies about fertility and pregnancy issues in young breast cancer patients: current state of the art.

Lambertini M, Goldrat O, Clatot F, Demeestere I, Awada A.

Curr Opin Oncol. 2017 Jul;29(4):243-252. doi: 10.1097/CCO.0000000000000380. Review.

PMID:
28463857
26.

Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.

Twelves C, Cortés J, O'Shaughnessy J, Awada A, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Rugo HS.

Eur J Cancer. 2017 May;76:205-215. doi: 10.1016/j.ejca.2017.02.011. Epub 2017 Mar 27.

27.

Checkpoint inhibitors in the treatment of brain metastases of non-small-cell lung cancer and melanoma.

Kourie HR, Kanaan H, Awada G, Awada AH.

Future Oncol. 2017 May;13(12):1097-1103. doi: 10.2217/fon-2016-0494. Epub 2017 Feb 28. Review.

PMID:
28326837
28.

A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.

Baselga J, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ, Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Pathiraja K, Gause C, Mauro D, Jones MB, Rugo HS.

Breast Cancer Res Treat. 2017 Jun;163(3):535-544. doi: 10.1007/s10549-017-4199-3. Epub 2017 Mar 21.

29.

Commentary.

Awada AA.

J Neurosci Rural Pract. 2017 Jan-Mar;8(1):138-139. doi: 10.4103/0976-3147.193554. No abstract available.

30.

The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges.

Solinas C, Chanzá NM, Awada A, Scartozzi M.

Cancer Treat Rev. 2017 Feb;53:138-145. doi: 10.1016/j.ctrv.2016.12.004. Epub 2016 Dec 30. Review.

PMID:
28113097
31.

Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation.

Cairns L, Aspeslagh S, Anichini A, Kyte JA, Blank C, Ascierto P, Rekers N, Straten PT, Awada A.

Ecancermedicalscience. 2016 Nov 10;10:691. eCollection 2016.

32.

Advances in chemical pharmacotherapy to manage advanced breast cancer.

Gombos A, Awada A.

Expert Opin Pharmacother. 2017 Jan;18(1):95-103. doi: 10.1080/14656566.2016.1269748. Epub 2016 Dec 16. Review.

PMID:
27927046
33.

Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.

Locatelli MA, Aftimos P, Dees EC, LoRusso PM, Pegram MD, Awada A, Huang B, Cesari R, Jiang Y, Shaik MN, Kern KA, Curigliano G.

Oncotarget. 2017 Jan 10;8(2):2320-2328. doi: 10.18632/oncotarget.13727.

34.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y.

ESMO Open. 2016 Sep 29;1(5):e000097. eCollection 2016. Review.

35.

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.

Tolaney SM, Nechushtan H, Ron IG, Schöffski P, Awada A, Yasenchak CA, Laird AD, O'Keeffe B, Shapiro GI, Winer EP.

Breast Cancer Res Treat. 2016 Nov;160(2):305-312. Epub 2016 Oct 6.

36.

Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors.

Aspeslagh S, Awada A, S Matos-Pita A, Aftimos P, Bahleda R, Varga A, Soria JC.

Anticancer Drugs. 2016 Nov;27(10):1021-7. doi: 10.1097/CAD.0000000000000409.

PMID:
27610894
37.

Testicular germ cell tumor: Short and long-term side effects of treatment among survivors.

Gil T, Sideris S, Aoun F, van Velthoven R, Sirtaine N, Paesmans M, Ameye L, Awada A, Devriendt D, Peltier A.

Mol Clin Oncol. 2016 Sep;5(3):258-264. Epub 2016 Jul 14.

38.

Are virus-induced cancers more sensitive to checkpoint inhibitors?

Kanaan H, Kourie HR, Awada AH.

Future Oncol. 2016 Dec;12(23):2665-2668. Epub 2016 Aug 11. No abstract available.

PMID:
27513334
39.

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.

Ignatiadis M, Zardavas D, Lemort M, Wilke C, Vanderbeeken MC, D'Hondt V, De Azambuja E, Gombos A, Lebrun F, Dal Lago L, Bustin F, Maetens M, Ameye L, Veys I, Michiels S, Paesmans M, Larsimont D, Sotiriou C, Nogaret JM, Piccart M, Awada A.

PLoS One. 2016 Jul 25;11(7):e0154009. doi: 10.1371/journal.pone.0154009. eCollection 2016.

40.

Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial.

Cortés J, Rugo HS, Twelves C, Awada A, Perez EA, Im SA, Zhao C, Hoch U, Tomkinson D, Buchanan J, Tagliaferri M, Hannah A, O'Shaughnessy J.

Springerplus. 2016 Jul 8;5(1):1033. doi: 10.1186/s40064-016-2446-4. eCollection 2016.

41.

Current-day precision oncology: from cancer prevention, screening, drug development, and treatment - have we fallen short of the promise?

Morgan G, Aftimos P, Awada A.

Curr Opin Oncol. 2016 Sep;28(5):441-6. doi: 10.1097/CCO.0000000000000318. Review.

PMID:
27428363
42.

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer.

Twelves C, Awada A, Cortes J, Yelle L, Velikova G, Olivo MS, Song J, Dutcus CE, Kaufman PA.

Breast Cancer (Auckl). 2016 Jun 28;10:77-84. doi: 10.4137/BCBCR.S39615. eCollection 2016.

43.

Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.

Kourie HR, Chaix M, Gombos A, Aftimos P, Awada A.

Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):947-57. doi: 10.1080/17425255.2016.1198317. Epub 2016 Jun 27. Review.

PMID:
27284682
44.

Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer.

Sideris S, Aoun F, Zanaty M, Martinez NC, Latifyan S, Awada A, Gil T.

Mol Clin Oncol. 2016 Jun;4(6):1063-1067. Epub 2016 Mar 17.

45.

Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.

Awada A, Cortés J, Martín M, Aftimos P, Oliveira M, López-Tarruella S, Espie M, Lardelli P, Extremera S, Fernández-García EM, Delaloge S.

Clin Breast Cancer. 2016 Oct;16(5):364-371. doi: 10.1016/j.clbc.2016.05.005. Epub 2016 May 14.

PMID:
27266804
46.

Drugs prescribed for patients hospitalized in a geriatric oncology unit: Potentially inappropriate medications and impact of a clinical pharmacist.

Deliens C, Deliens G, Filleul O, Pepersack T, Awada A, Piccart M, Praet JP, Lago LD.

J Geriatr Oncol. 2016 Nov;7(6):463-470. doi: 10.1016/j.jgo.2016.05.001. Epub 2016 May 26.

PMID:
27238734
47.

Rare side-effects of checkpoint inhibitors.

Kourie HR, Awada G, Awada AH.

Curr Opin Oncol. 2016 Jul;28(4):295-305. doi: 10.1097/CCO.0000000000000294. Review.

PMID:
27153354
48.

Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.

Aftimos P, Polastro L, Ameye L, Jungels C, Vakili J, Paesmans M, van den Eerenbeemt J, Buttice A, Gombos A, de Valeriola D, Gil T, Piccart-Gebhart M, Awada A.

Eur J Cancer. 2016 Jun;60:117-24. doi: 10.1016/j.ejca.2016.03.010. Epub 2016 Apr 20.

PMID:
27107326
49.

Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer.

Agarwal N, Machiels JP, Suárez C, Lewis N, Higgins M, Wisinski K, Awada A, Maur M, Stein M, Hwang A, Mosher R, Wasserman E, Wu G, Zhang H, Zieba R, Elmeliegy M.

Oncologist. 2016 May;21(5):535-6. doi: 10.1634/theoncologist.2015-0502. Epub 2016 Apr 18.

50.

Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.

Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, Lee SC, Mehta AO, Kim SB, Bachelot T, Goswami C, Deo S, Bose R, Wong A, Xu F, Yao B, Bryce R, Carey LA.

JAMA Oncol. 2016 Dec 1;2(12):1557-1564. doi: 10.1001/jamaoncol.2016.0237.

PMID:
27078022

Supplemental Content

Support Center